title: [Efficiency of an intensive stage of chemotherapy for tuberculosis in elderly and senile patients].
abstract: A hundred new cases of active pulmonary tuberculosis whose age was 60 to 87 years were treated by the intensive chemotherapy regimen recommended by the WHO. Most (n = 78) patients satisfactorily tolerated the intensive stage, fully completed the regimen, and made up a study group (Group 1). Group 2 comprised the remaining 22 patients who had, due to its poor tolerance, to transfer to their individual regimen. The higher incidence of significant cardiovascular diseases in Group 2 patients is the only significant difference between these two identified groups. The advantages of the standard chemotherapy regimen are the more rapid elimination of symptoms of tuberculous intoxication; the earlier and more frequent disappearance of Mycobacterium tuberculosis from the sputum even with the primary drug resistance of the causative agent; as well as a more frequent closure of decay cavities. The findings make it possible to recommend a wider use of the standard intensive chemotherapy regimens for elderly and senile patients with tuberculosis.
authors.forename: M A
authors.initials: MA
authors.lastname: Karachunskiĭ
authors.forename: T E
authors.initials: TE
authors.lastname: Uvarova
mesh_terms: D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000904:Antibiotics, Antitubercular / Q000008:administration & dosage / Q000627:therapeutic use; D000995:Antitubercular Agents / Q000008:administration & dosage / Q000627:therapeutic use; D048909:Diabetes Complications; D004359:Drug Therapy, Combination; D004977:Ethambutol / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007538:Isoniazid / Q000008:administration & dosage / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009169:Mycobacterium tuberculosis / Q000302:isolation & purification; D011718:Pyrazinamide / Q000008:administration & dosage / Q000627:therapeutic use; D012293:Rifampin / Q000008:administration & dosage / Q000627:therapeutic use; D012307:Risk Factors; D012737:Sex Factors; D013183:Sputum / Q000382:microbiology; D014397:Tuberculosis, Pulmonary / Q000150:complications / Q000188:drug therapy* / Q000382:microbiology; D014944:World Health Organization
chemical_list: D000904:Antibiotics, Antitubercular; D000995:Antitubercular Agents; D011718:Pyrazinamide; D004977:Ethambutol; D007538:Isoniazid; D012293:Rifampin